ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Leucovorin

Also written as “leucovorin”, “Folinic acid” and “FLOT Chemotherapy”.

Its studies are mostly in Colorectal Neoplasms · Neoplasms · Pancreatic Neoplasms · Carcinoma, Hepatocellular · Stomach Neoplasms, led by 21 companies.

Drug pageLeucovorin: every studyMany companies study it; this page follows only the 34 they lead. All 309 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since May 9, 200734 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofiits history only50 open or runningphase 3since May 9, 2007May 9, 2007none ahead
AstraZenecaits history only41 open or runningphase 2since Jul 17, 2003Jul 17, 2003Nov 9, 2027phase 2 · NCT07069712
Bristol-Myers Squibb40 open or runningphase 2since Jun 26, 2002Jun 26, 2002none ahead
Hoffmann-La Rocheits history only30 open or runningphase 2since Feb 26, 2010Feb 26, 2010none ahead
Pfizerits history only21 open or runningphase 3since Sep 1, 2005Sep 1, 2005none ahead
3SBioits history only11 open or runningphase 2since Jun 25, 2024Jun 25, 2024none ahead
AbbVieits history only11 open or runningphase 2since Oct 25, 2023Oct 25, 2023Dec 2026phase 2 · NCT06107413
Adherex Technologiesits history only10 open or runningphase 2since Oct 27, 2010Oct 27, 2010none ahead
Aurobindo Pharmaits history only10 open or runningphase 2since Mar 28, 2014Mar 28, 2014none ahead
Cardiff Oncologyits history only10 open or runningphase 2since Feb 9, 2021Feb 9, 2021none ahead

Also a collaborator on its studies: Ono Pharmaceutical, Parexel, Halozyme Therapeutics, BioLineRx, Axis Clinicals and Regeneron Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 26, 2002First study: phase 2 study in Colorectal NeoplasmsFirst studyNCT00040391 · United States
  2. Jan 11, 2010Phase 1 study in Pyloric Stenosis, HypertrophicNCT01046864 · 49 enrolled · United States, Canada, France
  3. Jun 9, 2017Phase 2 study in Colorectal NeoplasmsNCT03184870 · 332 enrolled · United States, Australia, Belgium and more
  4. Nov 6, 2017Phase 2 study in Advanced Pancreatic CancerNCT03336216 · 205 enrolled · United States, Canada, Denmark and more

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 Bristol-Myers Squibb leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03336216Advanced Pancreatic Cancer · United States, Canada, Denmark and more2CompletedJun 1, 2023205
NCT03184870Colorectal Neoplasms · United States, Australia, Belgium and more2CompletedApr 6, 2023332
NCT01046864Pyloric Stenosis, Hypertrophic · United States, Canada, France1CompletedJun 201449
NCT00040391Colorectal Neoplasms · United States2Terminated

How it is read

Names in the registry

  • “Leucovorin”, 18 entries
  • “leucovorin”, 4 entries
  • “Folinic acid”, 3 entries
  • “FLOT Chemotherapy”, 1 entry
  • “Folinic Acid”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.